•OCT biomarkers may predict DME treatment response•Alcon acquires Neurotech, MacTel therapy Encelto•Stuart Therapeutics submits IND amendment for corneal wound healing•EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout •Innovent's Sycume meets phase 3 endpoint for inactive TED•OCT biomarkers may predict DME treatment response•Alcon acquires Neurotech, MacTel therapy Encelto•Stuart Therapeutics submits IND amendment for corneal wound healing•EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout •Innovent's Sycume meets phase 3 endpoint for inactive TED
HEADLINES
FEATURED
US patients can now automatically enroll into the patient education and engagement platform via Promptly’s Patient Experience Suit
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
